Document is current
Any future updates will be listed below
-
Authors
Mahanani, Melani R. https://orcid.org/0000-0003-3391-934X
Neuhann, Florian https://orcid.org/0000-0001-5944-1597
Rambiki, Ethel https://orcid.org/0000-0001-9742-5707
Nhlema, Angelina
Tweya, Hannock https://orcid.org/0000-0002-8247-1273
Chit, Myo https://orcid.org/0009-0004-8711-8008
Chiwoko, Jane
Chaweza, Thom
Wallrauch, Claudia https://orcid.org/0009-0008-9180-0850
Heller, Tom https://orcid.org/0009-0008-4626-0592
Winkler, Volker https://orcid.org/0000-0002-9974-1145
Fätkenheuer, Gerd
Steffen, Hans-Michael https://orcid.org/0000-0001-6562-3549
-
Funding
Funding for this research was provided by:
Medizinische Fakultät Heidelberg der Universität Heidelberg
- License Information
-
More Information
Article History
Received: 13 January 2025
Accepted: 19 January 2026
First Online: 28 January 2026
Declarations
:
: The Lighthouse Tenofovir cohort study (LighTen, Clinical Trial number NCT02381275) was approved by Ethical Committees of the universities of Cologne (No. 14–251) and Heidelberg (No. S-293/2014) and the National Health Research Commission, Ministry of Health, Malawi (NHSRC Protocol #1199).
: Not applicable.
: The authors declare no competing interests.
